本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SINGAPORE, Dec. 6, 2024 /PRNewswire/ -- IMAGINE AI is the largest calendar event in Singapore that brings together the brightest minds in healthcare and artificial intelligence to explore the transformative potential of AI in healthcare. Hosted at the Marina Bay Sands Expo & Convention Centre, this biennial event features a diverse array of experts, practitioners, and innovators from across the globe and aims to inspire and engage more than 600 delegates and participants in the exploration of AI's capabilities in healthcare, fostering innovation and collaboration in the field. Speakers at IMAGINE AI 2024 include (from left) Adjunct Professor Ngiam Kee Yuan, Head, Academic Informatics Office, National University Health System (NUHS); Professor Chin Jing Jih, Deputy Group Chief Executive Officer (Clinical & Academic Development), National Healthcare Group; Assistant Professor Feng Mengling, Saw Swee Hock School of Public Health, National University of Singapore (NUS); Associate Professor Iain Tan, Deputy Group Chief Medical Informatics Officer (Research), SingHealth; Professor Thomas Coffman, Dean, Duke-NUS Medical School; Professor Yeoh Khay Guan, Chief Executive, NUHS; Professor Joseph Sung, Dean, Lee Kong Chian School of Medicine, Nanyang Technological University and Professor Liu Bin, Deputy President (Research and Technology), NUS. IMAGINE AI is a collaborative effort[1] organized by the three healthcare clusters, three medical schools, and Saw Swee Hock School of Public Health, and featuring more than 60 international and local speakers. The Guest-of-Honour is Mr Lew Chuen Hong, Chief Executive of Infocomm Media Development Authority (IMDA). For more information on this event, go to: https://sg-ai.org/ Key News Points 2. The IMAGINE AI opening day event saw the introduction of a nurse companion robot, the NUHS MiSSi Robot. It is a cloud-based robot, connected via a dedicated 5G network to a secured healthcare cloud to enable a range of AI functions. For example, it features an empathetic personality based on trained GPT models in the cloud. The MiSSi Robot is designed to support healthcare staff by taking over repetitive tasks. It autonomously assists nurses with tasks such as like vital sign monitoring, averting falls in the ward, last mile delivery and patient interaction, enhancing the efficiency of ward activities. It features swappable 'smart' compartments and a robot arm for versatile roles in consumable logistics and delivery in healthcare settings. MiSSi is also capable of conversing with patients, providing a personalised care to patients with empathy and humour. Head, Academic Informatics Office, NUHS, Adjunct Professor Ngiam Kee Yuan added, "We are at the final prototype stage of MiSSi robot and piloting at NUH ward with a plan to scale it to more settings." 3. This biennial event also saw the announcement of the establishment of a new centre for AI in Public Health by the Saw Swee Hock School of Public Health. This centre slated to be launched early next year, aims to create AI solutions specifically designed to address public health challenges, in collaboration with the World Health Organization and regional health ministries. In close collaboration with the World Health Organization (WHO) and Ministries of Health across the region, the centre is committed to deploying these innovative AI solutions to drive positive impact and advance health equity for the populations of Southeast Asia. The centre's mission also includes empowering local health officials and developing a regional talent pool to drive positive impact and advance health equity in Southeast Asia, through education and training. As the centre focused on public health, there will be a lot more focus on preventive health, behaviour nudging and education of population, so that the population will be better informed, develop a healthier lifestyle, participate in screening for early detection of diseases and more effective treatments. Assistant Professor Feng Mengling said, "Our centre will also focus on developing predictive AI models to identify high-risk sub-populations for chronic diseases or other health conditions. This will enable timely preventive measures or early treatments to improve outcomes. Moreover, we will develop AI-powered surveillance systems for the early detection of potential outbreaks of infectious diseases, allowing us to proactively prepare for and mitigate pandemics rather than merely reacting to them. Our centre will collaborate with regulators to establish robust laws and guidelines, ensuring that AI solutions are developed and deployed responsibly and ethically. By doing so, we strive to create a future where everyone has an equitable opportunity to achieve better health outcomes." 4. The first two days of IMAGINE AI 2024 feature a diverse array of sessions, including keynote talks, panel discussions, and industrial panels. Notable speakers include Dr. Andrew Ng, Founder of DeepLearning.AI, Founder & CEO of Landing AI, General Partner at AI Fund, Chairman and Co-Founder of Coursera and an Adjunct Professor at Stanford University's Computer Science Department, who will discuss the future of AI in healthcare. This would be followed by Prof. Leo Celi, from the Massachusetts Institute of Technology (MIT) who will address the challenges of AI bias. Dr. Junaid Bajwa, Senior Partner at Flagship Pioneeringwho will share insights on the. The programme also includes sessions on AI for diagnostics, clinical implementation, and public health, providing a comprehensive overview of AI's potential in healthcare. The last two days of IMAGINE AI on the 7 and 8th December features a two-day Datathon, where contestants will participate in a rapid data science problem solving on large healthcare datasets to compete for a prize of $10,000. 5. NTU Senior Vice-President (Health and Life Sciences) and LKCMedicine Dean Distinguished University Professor Joseph Sung said: "The Lee Kong Chian School of Medicine (LKCMedicine) is proud to be one of the organisers of IMAGINE AI, bringing together leading voices from Singapore and beyond to explore the promise and challenges surrounding AI in medicine and healthcare, and to spark collaborations. It is important for a medical school like LKCMedicine to be part of these discussions so that we can better prepare our future doctors and teach responsible AI use in clinical practice." 6. In a noteworthy announcement at the latest edition of IMAGINE AI, Duke-NUS Medical School unveiled the Duke-NUS AI + Medical Sciences Initiative (DAISI). Led by Associate Professor Liu Nan from Duke-NUS's Centre for Quantitative Medicine, the initiative brings AI and data science experts and clinicians together to innovate novel AI-based solutions to real-world clinical problems. Comprising globally renowned biomedical and healthcare researchers, the DAISI team spearheads research on cellular data science, immunology, quantum computing and even AI governance and ethics. The initiative is not only invested in developing groundbreaking methodologies but is also committed to turning its findings into practical interventions that are beneficial to healthcare professionals and patients. Key speakers and key points a) Assistant Professor Feng Mengling from NUS shares his project of having an AI assistant for faster triage in emergency services and collaborative AI for treatment recommendations, aimed at improving healthcare efficiency and outcomes. It is an AI Assistant for faster and better triage for 995. He will also touch on the transformative potential and uses of AI in healthcare, from improving diagnostic accuracy to enhancing patient management and treatment processes. b) Dr. Lucinda Tan, Senior Consultant from NHG's National Skin Centre (NSC), in collaboration with EyRIS and the Agency for Science, Technology and Research (A*STAR) Institute for Infocomm Research (I2R), has incorporated Artificial Intelligence (AI) into mobile applications to assist in the screening and early detection of skin cancers. SkAI is an integrated system, with SkAI Lite designed for patients and public use to capture images of skin lesions with their mobile phone cameras. Its inbuilt algorithm can analyse and classify the risk of the skin lesion being cancerous. SkAI Pro is designed for clinicians, used in tandem with an attachable dermoscope to capture dermoscopic images of lesions for clinical assessment. SkAI Lite and SkAI Pro is a seamless system that facilitates comprehensive skin cancer detection and monitoring, allowing for timely intervention. c) Dr Shum Cheuk Fan, Senior Consultant Urologist, Department of Surgery from NHG's Woodlands Health (WH), in collaboration with NDR Medical Technology, is developing a Robotic- and AI-Assisted Fluoroscopic-Guided Renal Access System called ANT-X to assist clinicians in precise instrument alignment for minimally invasive percutaneous procedures. Percutaneous Nephrolithotripsy (PCNL), the current standard of care for Nephrolithiasis, is the most effective procedure to remove large kidney stones and requires accurate placement of the needle. ANT-X's AI software allows full automation of its system calibration and the needle alignment with a single fluoroscopic image, allowing clinicians to focus solely on controlling the depth of needle insertion. It has been tested in over 80 cases of PCNL and has demonstrated increased first puncture success rates to 100%, greater puncture accuracy, and reduced procedural time. ANT-X is a Health Sciences Authority (HSA)-approved Class B medical device, and the project team has been awarded with the National Health Innovation Centre Singapore (NHIC) Innovation-to-Adopt grant to support its evaluation of clinical performance and adoptability for PCNL procedures in Singapore public health institutions. d) Assoc Prof Hairil Rizal Abdullah, Senior Consultant Anaesthesiologist and Clinician Scientist from SGH talks about a clinically oriented Generative AI Large Language Model called PEACH, which assists doctors in clinical decision making to ensure a more comprehensive, evidence-based, uniform and efficient optimisation plan for patients. Notable AI showcase 1) Survey on Gastroenterologists' Trust and Acceptance of AI: An international study led by LKCMedicine surveyed 165 gastroenterologists and gastrointestinal surgeons in the Asia Pacific region and found that gastroenterologists generally trust AI tools for diagnosing digestive diseases. Published in the scientific journal JMIR AI, findings from the study highlighted that more experienced doctors showed more confidence and discernment about addressing AI risks, in comparison to younger doctors. 2) Increasing the accuracy and reliability of large-scale study of proteins: High-throughput technologies for measuring genes, proteins, and metabolites are vital for advancing our understanding of biological systems and discovering novel biomarkers and drug targets. However, the data generated from these technologies in proteomics—the large-scale study of proteins—is complex, high-dimensional, and requires extensive processing. A study led by LKCMedicine tested over 34,000 workflow combinations on reliable datasets, uncovering consistent patterns among the top-performing workflows and demonstrated their predictability. Using this information, the team developed machine learning models capable of accurately predicting optimal workflows and introduced a novel method called "ensemble inference," which integrates results from the best workflows to enhance coverage and resolve inconsistencies. The study, which is published in Nature Communications, is the first to highlight AI's role in optimising data processing workflows, and underscores that AI not only enhances data quality assurance but also plays a critical role in ensuring the generation of high-quality models by starting with high-quality data. 3) CHAMP Program: This initiative promotes chronic disease management through an automated chatbot that calculates the patient's risks and provides personalised nudges to patients. The program is integrated with patient's electronic health record and supports patients, clinicians and care coordinators to provide population scale community-based care for chronic diseases. Developed by NUHS, CHAMP uses whatsapp nudges to support patient self-management in chronic disease and to encourage healthier lifestyles. It enables patients to effortlessly submit vital signs readings like blood pressure, sugar readings and other information via the whatsapp-based chatbot and is seamlessly integrated into the patient's medical record for continuity of care. More about this the CHAMP Chatbot Dr Wayne Han Lee, Assistant Group Chief Technology Office of NUHS, CHAMP program lead and family physician at the National University Polyclinics shared some benefits of the whatsapp-based chatbot: CHAMP can remind patients to input their blood pressure throughout the week. Dr Lee said, "Currently, patients would write their blood pressure readings on a piece of paper, and I've got to spend time trying to make sense of it. But with this chatbot, the patient's data is recorded in our system, and it shows me immediately what their maximum, minimum, and average blood pressure trend during the week. So, I can spend more time talking with our patients to find out more about them, rather than staring at a computer screen keying in and looking for information." This chatbot serves a dual purpose in that it not only offers clinicians a more efficient way of processing information, but also provides patients with an easier way of recording their medical information. With more than 9,000 NUHS patients currently enrolled on the CHAMP program, Dr Lee hopes to extend CHAMP to over 150,000 patients with one or more chronic diseases. While this chatbot has currently been rolled out within NUHS, Dr Lee shared, "We want to extend this automation service to all patients, GPs and doctors across the country". 4) Novel ethics assessment tools for AI applications in healthcare: the development of the Transparent Reporting of Ethics for Generative AI (TREGAI) checklist and CARE-AI consensus research are two key achievements of Duke-NUS' DAISI initiative. A pioneering tool that standardises ethics assessments for implementing GenAI in healthcare settings, the TREGAI checklist helps to mitigate ethical concerns identified during the researchers' scoping review of existing discourse on GenAI use. The CARE-AI consensus, an ethics assessment tool that is currently being developed by DAISI, will ensure that AI prediction models are implemented in a fair, trustworthy and ethical manner to improve patient care. Considering various factors, including disease conditions and geo-economic contexts, it will guide healthcare professionals across the different stages of making medical decisions involving AI. 5) RUSSELL-GPT is a secured clinical large language model tool platform for healthcare that features multiple large language model tools for healthcare use. It is designed and customised for a wide variety of clinical tasks that supports clinicians in reduce their administrative workloads. For example, it is routinely used to generate medical summaries, draft referrals, improve medical coding and documenting communication. One of its component tools is a medical voice-to-document program called Medivoice. It is widely used by nurses in NUHS to document daily clinical activities in clinical settings. It is also used to document communications with patients and caregivers which are a time consuming, but essential part of clinical care. In a study of NUHS clinicians who use this tool for the summarisation task vs those who didn't showed a 40% increase in efficiency in generating the same summary. Dr Andrew Makmur, Group Chief Technology Officer, and Dr Clara Ngoh, Assistant Group Chief Technology Officer, shared that RUSSELL-GPT is now the default generative AI tool used by over 2000 staff in NUHS and continues to grow in its capability and adoption. 6) For non-clinical and back-of-house users, the homegrown Bot-NUHS, an AI-powered assistant, is redesigning healthcare operations to drive productivity and efficiency. The bot is designed to enhance both patient-facing and back-of-house operations within NUHS. It leverages advanced AI technologies to provide quick and precise responses, improving patient experience and operational efficiency. The bot's capabilities include sentiment analysis, procurement guidance, and clinical practice information retrieval, making it a comprehensive tool for healthcare operations. More about Bot-NUHS It can measure and utilize the following specific data points: a) Procurement Data: It provides guidance and quick responses to procurement-related inquiries, such as SRF material codes. b) Clinical Practice Information: The bot assists polyclinic doctors by retrieving clinical practice guide information more quickly and accurately, thereby enhancing productivity. c) Patient Feedback: It analyzes patient feedback using natural language processing to uncover key themes and insights, which helps improve patient services. d) Job Applicant Data: The bot screens high volumes of job applicants, effectively parsing resumes to surface qualified candidates, thus reducing time-to-hire. e) Corporate Policy Queries: It provides quick answers to corporate policy questions, reducing the workload for policy teams. f) Employee Feedback: The bot analyzes employee feedback using sentiment analysis and theme extraction to provide data-driven insights for addressing concerns. Application of Bot-NUHS A team of Supportive and Palliative Care nurses from Alexandra Hospital uses AI to communicate complex medical information to patients from diverse cultural backgrounds. These nurses who work with discharged patients at home and in the community, offer tele-support services to caregivers. Now with the implementation of the homegrown Bot-NUHS AI system, nurses can now translate lengthy, complicated discussions like Advanced Care Planning into different languages such as Mandarin. The Bot-NUHS AI further simplifies these conversations into layman terms for easier comprehension by patients. It also enables the care team to quickly generate a condolence message for a bereaved family member. It is also utilized to swiftly provide tailored education and advice to caregivers as needed. This saves nurses' time from having to manually type out these communications, thereby enhancing workflow efficiency. 7) SingHealth's A/Prof Zhong Liang is leading the APOLLO project, AI in Cardiovascular Care, which aims to develop a national AI platform for Computed Tomography Coronary Angiography, significantly improving diagnostic speed and accuracy. APOLLO aims to develop a national platform driven by artificial intelligence for Computed Tomography Coronary Angiography, to cater to clinical, research, and industrial applications for Coronary Artery Disease. It will serve as a one-stop solution spanning from diagnosis and clinical management to prognosis. Additionally, it will aid in predicting how patients response to therapy in the pharmaceutical sector. APOLLO is a collaborative effort involving the three largest national heart centres among the public healthcare clusters, as well as A*STAR and universities. Since its initial introduction in 2022, APOLLO has achieved significant milestones, having successfully recruited 5000 patients for its projects. Notably, it has been demonstrated that the AI-powered CT image reader (version 1.0) is 20 times faster and just as accurate as clinician readers. Project APOLLO will soon be testbeded in three healthcare clusters (i.e. SingHealth, NUHS and NHG). 8) SingHealth implements Note Buddy to transform clinical documentation and enhance the quality of doctor-patient interactions. All healthcare professionals across SingHealth institutions will progressively be onboarded to Note Buddy which aims to significantly reduce administrative burden by transcribing and summarising clinical notes in real-time during physician-patient conversations. This allows clinicians to dedicate time during each consultation to interacting with patients and their caregivers to better understand and address their health concerns and questions. More about Note Buddy Note Buddy's key feature is its ability to automatically detect, transcribe and summarise conversations in multiple languages (English, Mandarin, Malay and Tamil) between the clinician and patient during clinic consultations into accurate clinical notes using customised prompts that structure how the clinical note is summarised. Speaker diarisation allows Note Buddy to differentiate multiple speakers and identify their role based on the context (e.g. Doctor, Patient, Caregiver). Developed by SingHealth's Division of Digital Strategy, Note Buddy is launched on Tandem, a Secure Generative Pre-trained Transformer (GPT) platform developed by Synapxe, Singapore's HealthTech agency. Currently, healthcare professionals document clinical notes during consultations with patients. Note Buddy heralds a paradigm shift in the way clinical documentation is done. Before the consultation, clinicians can select a customised prompt in Note Buddy to tailor the format of the notes to their specialty. For instance, an endocrinologist can use Note Buddy to document patient-reported insights, diabetes and thyroid assessments, as well as cardiometabolic management plans during consultations, ensuring that these key pieces of information are captured. Note Buddy extracts and summarises the relevant information shared during the doctor-patient conversation into clinical notes in real time. Clinicians can review the notes immediately after each consultation to ensure that the necessary information has been accurately documented. This process enhances the timeliness, completeness and accuracy of each clinical documentation. Note Buddy also has capabilities beyond clinical consultations including text summarisation. Clinically, it assists in summarising clinical notes into various structured documents such as discharge summaries and medical reports. On the administrative front, Note Buddy can handle administrative tasks like drafting meeting minutes. This expansion of its capabilites streamlines both clinical and administrative workflows, reducing the documentation burden on healthcare professionals and administrators. [1] Singapore's leading healthcare and academic institutions are featured, including the National University of Singapore (NUS), National University Health System (NUHS), SingHealth, National Healthcare Group (NHG), the Lee Kong Chian School of Medicine (LKC Medicine) at Nanyang Technological University, Singapore (NTU Singapore) and Duke-NUS Medical School, as well as Saw Swee Hock School of Public Health.
OSAKA, Japan and MONTREAL , Dec. 6, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; "Ono") announced that it has entered into a drug discovery collaboration agreement with Congruence Therapeutics (Headquarters: Montreal, Quebec, Canada; CEO: Clarissa Desjardins; "Congruence") to generate novel small molecule correctors against multiple protein targets in the oncology area by leveraging Congruence's proprietary drug discovery platform, Revenir™. Under the terms of the agreement, Congruence will generate small molecule correctors by leveraging Congruence's proprietary drug discovery engine called, Revenir™. Ono will obtain an exclusive option right to develop, manufacture and commercialize the identified small molecule correctors worldwide. Congruence will be eligible to receive an upfront payment, research expenses, milestone payments based on research and development progress and sales, as well as tiered royalties based on net sales. "We believe that this collaboration with Congruence may help generating novel small molecule correctors for validated targets in the oncology area by leveraging their own technologies in protein dynamics and computational biology, leading to our development pipeline," said Seishi Katsumata, Corporate Officer / Executive Director, Discovery & Research of Ono. "We will be committed to delivering innovative new drugs to cancer patients as soon as possible." "Congruence is thrilled to partner with Ono, which has established itself as a global leader in drug development, particularly in the oncology space. We believe that our Revenir™ platform and capabilities in protein dynamics will accelerate the discovery of novel therapies for compelling targets of interest to both companies," said Sharath Hegde PhD, Chief Scientific Officer of Congruence. About Revenir™ Drug Discovery Platform Revenir™, Congruence's proprietary computational drug discovery platform, captures the dynamic biophysical changes caused by mutations in proteins, offering unique insights into protein defects and their correction. By examining surface features and a spectrum of biophysical descriptors across an ensemble of protein conformers, Revenir™ predicts small molecule induced correction of the underlying defect. About Congruence Therapeutics Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Congruence's proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter. For more information, please visit www.congruencetx.com.
Lunit and Volpara revealed a unified Ecosystem at RSNA 2024, featuring AI-powered cancer risk prediction, autonomous report generation, and innovations to transform global cancer care SEOUL, South Korea, Dec. 5, 2024 /PRNewswire/ -- At this year's RSNA 2024 Annual Meeting, Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, and Volpara Health, a Lunit company and a global leader in mammography AI for the early detection of cancer, announced their unified vision, focusing on a comprehensive Ecosystem for early cancer detection, cancer risk prediction, and autonomous AI for enhanced clinical workflows. A Lunit representative demonstrates the Autonomous Chest X-Ray Report Generation prototype to booth visitors at RSNA 2024, showcasing how AI-driven automation is transforming diagnostic workflows. (Courtesy of Lunit) Lunit Booth at RSNA 2024 A Growing Ecosystem for Cancer Detection and Care At the core of Lunit and Volpara's unified strategy is a comprehensive Ecosystem designed to support clinicians and improve patient outcomes across the entire cancer journey. The Ecosystem delivers actionable insights that enhance care quality and efficiency by integrating AI-driven technologies for lesion detection, workflow optimization, and patient engagement, with decision-making insight through risk prediction and mammography quality control. Powered by world-class AI, including physics-based algorithms and access to over 130 million images for research and development, the Ecosystem drives accurate, efficient, and scalable solutions for cancer detection. Focusing on customer obsession, the Ecosystem also provides dedicated support, professional services, and fosters an exclusive online community to ensure clinical success and operational excellence. Additionally, future multipliers like autonomous AI, intelligent report generation, and image-based risk evaluation are set to redefine the standards of cancer care globally. Lunit INSIGHT Risk and Volpara Risk Pathways: Transforming Risk Assessment As part of their collaboration, Lunit and Volpara presented a powerful combination of Lunit INSIGHT Risk and Volpara Risk Pathways, offering a comprehensive approach to breast cancer risk management. Lunit INSIGHT Risk uses AI-driven imaging data to predict breast cancer risk within 1-5 years, providing actionable insights based on mammography images. Volpara Risk Pathways incorporates clinical and lifestyle data to deliver broader, personalized risk assessments. Together, these solutions enable clinicians to create tailored care plans, enhance early detection strategies, and ensure equitable care for diverse patient populations. Expanding AI Innovation: Autonomous Chest X-Ray Report Generation At RSNA 2024, Lunit also introduced its Autonomous AI Chest X-ray Report Generation prototype, showcasing its potential to revolutionize diagnostic workflows. Using advanced foundation models, the system automates chest X-ray interpretations and generates structured reports. By analyzing and categorizing findings based on severity, measurement, and location, the tool ensures precision and standardization in reporting. This innovation significantly reduces radiologist workloads, especially in high-volume clinical environments, while improving diagnostic efficiency. By automating time-consuming processes, it enables radiologists to focus on complex and critical cases, ensuring timely and accurate patient care. As an additional feature, the tool includes voice recognition capabilities, allowing radiologists to make edits and finalize reports seamlessly, further enhancing workflow flexibility and usability. Driving Global Market Expansion The collaboration between Lunit and Volpara underscores their shared commitment to conquering cancer together and leading the global fight against cancer. Together, they aim to expand their presence in key markets by leveraging the Ecosystem, advanced AI solutions like Lunit INSIGHT Risk, and innovative tools such as autonomous report generation. "This year's RSNA marks an important milestone in our collaboration with Volpara," said Brandon Suh, CEO of Lunit. "By integrating our complementary technologies, we are transforming the way clinicians detect cancer, predict risk, and manage workflows. This Ecosystem is more than a set of tools. It's a global solution designed to empower healthcare providers, reduce disparities, and ultimately save more lives; the next frontier in cancer care." "Our partnership with Lunit has allowed us to combine decades of expertise in AI and personalized care to create a truly unified Ecosystem," said Teri Thomas, CEO of Volpara Health and CBO of Lunit Cancer Screening Group. "Together, as part of the same family, we're addressing some of the most pressing challenges in cancer care—from empowering clinicians with actionable insights to improving outcomes for patients around the world. We're proud to showcase the tangible impact of this integration, which is already shaping the future of global cancer detection and care." About Lunit Founded in 2013, Lunit (KRX:328130.KQ) is a medical AI company on a mission to conquer cancer. We harness AI-powered medical image analytics and AI biomarkers to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,500 hospitals and medical institutions across 55+ countries. Lunit clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as ASCO and RSNA. In 2024, Lunit acquired Volpara Health Technologies, setting the stage for unparalleled synergy and accuracy, particularly in breast health and screening technologies. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more at lunit.io. About Volpara Health Volpara Health is on a mission to save families from cancer with AI-powered software that helps healthcare providers better understand cancer risk, guide personalized care decisions, and recommend additional imaging and interventions. Used in over 3,500 facilities by more than 9,500 technologists worldwide. Volpara's software impacts nearly 18M patients, supports over 3.6M annual cancer risk assessments, and integrates seamlessly with electronic health records and imaging systems. Volpara helps radiologists quantify dense breast tissue with precision and technologists produce mammograms with optimal positioning, compression, and dose. Volpara software also streamlines operations to ease compliance and accreditation. Volpara, a Lunit company, is headquartered in Wellington, New Zealand, and has an office in Seattle. Volpara is the trusted partner of leading healthcare institutions globally. For more information, visit www.volparahealth.com.
Demonstrates MS Analysis Technology, Recently Secured FDA 510(k) Clearance Introduces 'Neurophet AQUA AD,' a Total Solution for Alzheimer's Disease Treatment Prescription, at the AI Theater SEOUL, South Korea, Dec. 5, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced its participation in the Radiological Society of North America 2024 (RSNA 2024). Jake Junkil Been, Co-CEO of Neurophet, presenting at the AI Theater during RSNA 2024 At this conference, Neurophet unveiled its brain MRI analysis software, 'Neurophet AQUA', now enhanced with MS analysis functionality, for the first time. This product recently received additional FDA 510(k) Clearance. The MS analysis technology quantifies lesions and structural changes, enabling precise measurement of lesion count, volume, and progression. This enables objective assessment of treatment efficacy by confirming changes in lesions following the prescription of MS treatment. Notably, it delivers robust segmentation across both 2D and 3D imaging methods of T2-FLAIR MRI at 1.5T and 3.0T, while also enabling volumetric analysis of brain regions without requiring 3D T1 imaging. Neurophet also showcased the total solution for Alzheimer's disease treatment, 'Neurophet AQUA AD', at the exhibition booth. Neurophet AQUA AD provides comprehensive brain imaging biomarker analysis features required during the administration of anti-amyloid treatments by quantitatively analyzing MRI (magnetic resonance images) and PET (positron emission tomography) images. It supports evaluating patient eligibility for treatment, monitoring ARIA (amyloid-related imaging abnormalities), and analyzing treatment effects based on the reduction of amyloid beta deposited in the brain, aiding decisions on whether to continue, pause, or discontinue treatment. In the AI Theater session, Jake Junkil Been, Co-CEO of Neurophet, delivered an oral presentation on the topic of "Neurophet in the Alzheimer's Paradigm Shift Era." He emphasized the importance of utilizing AI technology for the early detection and monitoring of ARIA to enhance the efficacy and safety of Alzheimer's disease treatments. "Our focus remains on advancing the technological capabilities required to meet global demands in areas such as MS and Alzheimer's disease treatments," said Jake Junkil Been, Co-CEO of Neurophet. "The debut of Neurophet AQUA's MS analysis capabilities at RSNA, following FDA 510k clearance, marks a significant step in our strategy to expand our presence in international markets." RSNA is the world's leading radiology conference, bringing a wide range of medical imaging devices and newly emerged innovative technologies. Experts and professionals from academia, healthcare, and industry in the field of radiology worldwide gathered, which took place in Chicago, USA, from December 1st to 5th this year. About Neurophet Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain diseases based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system. Major products include brain MRI analysis software "Neurophet AQUA", brain PET image analysis (PET tracer deposition) software "Neurophet SCALE PET", brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB". Neurophet has set its top priority to helping patients suffering from brain diseases. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.
First and only contact force pulsed field ablation (PFA) system engineered to revolutionize care for the hundreds of thousands at risk of death from ventricular tachycardia (VT). FDA's TAP Pilot and Breakthrough Device Designation are awarded to medical devices that could provide more effective treatment compared to existing approved treatments, reflecting the agency's commitment to expediting patient access to innovative, safe, and effective therapies. CARDIFF-BY-THE-SEA, Calif., Dec. 5, 2024 /PRNewswire/ -- Field Medical® Inc., a leader in pulsed field cardiac catheter ablation technology, announced today that its FieldForce™ Ablation System has been accepted into the FDA's Total Product Life Cycle Advisory Program (TAP) Pilot and granted Breakthrough Device Designation for sustained monomorphic scar-related ventricular tachycardia (VT). This recognition underscores the system's groundbreaking approach to addressing life-threatening VT and the critical unmet needs for patients worldwide. Pre and post voltage map demonstrating Field Medical’s technology creating transmural LV ablation lesions from endocardial treatment alone. This image is from a VCAS Study subject treated with FieldForce for VT Ablation. "The FDA's TAP Pilot acceptance and Breakthrough Device Designation for the FieldForce™ Ablation System represent pivotal milestones in our journey to regulatory approval," said Dr. Steven Mickelsen, CEO of Field Medical. "This recognition advances our vision of equipping electrophysiologists with a next-generation, focal PFA tool for fast, accessible VT care." Dr. Vivek Reddy, Director of Electrophysiology at Mount Sinai Health System, added, "The FDA's recognition of this breakthrough technology underscores the urgent need for innovation in treating complex, life-threatening ventricular tachycardia. Field Medical's ablation system has the potential to redefine VT care for physicians and patients alike." The FieldForce™ Ablation System is the first and only PFA system specifically designed for ventricular arrhythmia ablation. Catheter ablation has been shown to be superior to medical therapy in patients at risk of sudden cardiac death (SCD) from VT (Sapp et al., 2024). SCD, which accounts for approximately 450,000 deaths annually in the United States alone (Mason et al., 2022) is often attributed to VT. Current pharmacological therapies are limited in efficacy, with 30-50% of patients with VT not responding well to traditional drug treatments (Kircher et al., 2023). The emerging science highlights the pressing need for innovative solutions like the FieldForce™ Ablation System. About Field Medical® Inc.Founded in 2022, Field Medical is advancing next-generation pulsed field ablation (PFA) technologies to address the complex needs of modern cardiac ablation. The company is led by Dr. Steven Mickelsen, a pioneer in pulsed electric field technology and one of the foremost innovators in the field. Dr. Mickelsen's foundational work in PFA established the basis for modern advancements in the technology, which Field Medical continues to refine with its groundbreaking solutions. The company's proprietary FieldBending™ technology and comprehensive product portfolio, including the FieldForce™ Catheter, FieldForce™ Ablation System, and FieldFlex™ Sheath, are designed to expand PFA applications beyond atrial fibrillation to treat complex ventricular arrhythmias. Field Medical is committed to advancing patient outcomes through innovation, transforming cardiac care for the millions impacted by these life-threatening conditions worldwide. About FieldForce™ Ablation System. The FieldForce Ablation System features a single-point contact force PFA catheter with an innovative design utilizing proprietary FieldBending™ technology to deliver targeted, brief, high-intensity electric fields. This next-generation PFA technology was designed to deliver both precise targeted lesions and large volume transmural lesions in the ventricle. For more information, visit www.fieldmedicalinc.com and follow us on LinkedIn and X. The FieldForce™ PFA Ablation System is an investigational device and is limited by Federal (or United States) Law to investigational use. Media ContactHolly Windler619.929.1275 References:Mason, J., et al. (2022). "Trends in Sudden Cardiac Death Due to Ventricular Tachycardia and Fibrillation in the United States." Circulation Research.Kircher, A., et al. (2023). "Efficacy of Antiarrhythmic Medications in the Treatment of Ventricular Tachycardia: A Review." Journal of the American College of Cardiology.Sapp, J., et al. (2024). "Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia." The New England Journal of Medicine. DOI: 10.1056/NEJMoa2409501. Photo - https://mma.prnasia.com/media2/2574172/Field_Medical_FieldForce_PFA___Full_Thickness_Endocardial_Ablation.jpg?p=medium600Logo - https://mma.prnasia.com/media2/2574173/Field_Medical_Logo_Block_WhiteOnBlack_Logo.jpg?p=medium600
HONG KONG SAR - Media OutReach Newswire - 5 December 2024 - Southco's new AC-50 Squeeze Handle Actuator features a dual cable pull system, enabling greater freedom in actuator positioning and secure multi-point latching on larger panels. This gives end users an ergonomic operating experience without compromising security. AC-50 Squeeze Handle Actuator As panels get larger, they become more difficult to secure. Multi-point latching is an effective solution to this problem, since multiple rotary latches can apply consistent force across the entire panel, preventing warping and leakage. However, it usually comes with complications since the latches need to be attached to an actuator by a single cable pull. This either limits where designers can place their actuator, or adds additional hardware to a design. Southco's AC-50 Multi-Point Squeeze Handle solves these issues with integrated symmetrical conduit cable mounting brackets and aluminum die cast levers for high pre-loads which pair with cable barrel fittings that eliminate the need for additional cable clips. Designers can freely mount this actuator on their application and use the two cables supported by it to actuate a multi-point latching system across the entire panel with minimal additional hardware. The actuator mounts to tubular structures or round surfaces, with thru hole surface mounting. Versatility, ergonomics, and durability make the Southco AC-50 Squeeze Handle Actuator an ideal solution for large panels where security is paramount. For more information about the AC-50 Squeeze Handle Actuator, visit www.southco.com/AC-Actuactors or email the 24/7 customer service department at info@southco.com. Hashtag: #southco #latchingsolutions #multiple #touchpointThe issuer is solely responsible for the content of this announcement.About SouthcoSouthco, Inc. is the leading global designer and manufacturer of engineered access solutions. From quality and performance to aesthetics and ergonomics, we understand that first impressions are lasting impressions in product design. For over 70 years, Southco has helped the world's most recognized brands create value for their customers with innovative access solutions designed to enhance the touch points of their products in transportation and industrial applications, medical equipment, data centers and more. With unrivalled engineering resources, innovative products and a dedicated global team, Southco delivers the broadest portfolio of premium access solutions available to equipment designers throughout the world.
A12 藝術空間
Medical Equipment
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
